The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument
A guideline listing is the first thing a payer asks a device maker for, and Neuromod’s Lenire now has one in tinnitus.
Neurology
Out of 452 Brain Regions, an Overlooked Hypothalamic Nucleus Set the Volume on Stress in Mice
Out of 452 brain regions mapped in mice, an overlooked hypothalamic nucleus carried the memory of past stress.
Genentech Paid $100 Million for Alector’s Parkinson’s Enzyme but Not Its Brain Shuttle
Genentech bought the Parkinson’s enzyme and left the brain shuttle with Alector, which now funds its pipeline into 2029.
Latvia Squeezes Access for 123,000 Patients Out of Price Deals as 124 Drugs Wait
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
AbbVie Largely Dropped Its Constitutional Case but Still Says Botox Is Plasma-Derived and Exempt
Constitutional challenges to Medicare negotiation have failed repeatedly. AbbVie is now betting on the definition of its product.
Caplyta Doubled the Mania Response Rate, and Only Dry Mouth and Nausea Cleared J&J’s Side Effect Bar
The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie’s Vraylar.
A Custom ALS Drug Took Three Years to Build and One Year to Normalise One Man’s Neurofilament
Built in about three years for one mutation, it normalised a biomarker in one man. A larger cohort sits outside the paper.
Japan Clears Five Products in a Day, Two With a Price Cut Attached
Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.
NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day
The NDA and the enrolment pause went out in one release. Xenon says the events match the mechanism, not the indication.